COMMENTARY

7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?

May 27, 2016
The health ministry has selected seven drugs that will go through a new pilot-based cost-effective assessment scheme and decided to re-price them in April 2018, but just how remains unclear. The ministry appears to be still pondering ways to weave…

To read the full story

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…